Eribulin-A review of preclinical and clinical studies

Critical Reviews in Oncology/Hematology

Volumn 81, Issue 2, 2012, Pages 163-184

  Swami, Umang ^a   Chaudhary, Imran ^a   Ghalib, Mohammad H ^a   Goel, Sanjay ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; E7389; EMBRACE; Eribulin; Halaven ; Halichondrin B; Microtubule inhibitor; NSC 707389

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERIBULIN; GEMCITABINE; KETOCONAZOLE; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL GROWTH; COLON CANCER; DEHYDRATION; DIZZINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSPORT; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FIBROSARCOMA; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPOGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IC 50; IN VITRO STUDY; INFECTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOPENIA; LUNG CANCER; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHARMACOLOGICAL BLOCKING; PROSTATE CANCER; REVIEW; SARCOMA; SENSORY NEUROPATHY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT TUMOR;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; FURANS; HUMANS; KETONES; NEOPLASMS;

EID: 84856235418     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.03.002     Document Type: Review

References (87)

1. Uemura D., Takahashi K., Yamamoto T., et al. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J Am Chem Soc 1985, 107(16):4796-4798.
2. Hirata Y., Uemura D. Halichondrins-antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986, 58(5):701-710.
3. Pettit G.R., Herald C.L., Boyd M.R., et al. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem 1991, 34(11):3339-3340.
4. Pettit G.R., Tan R., Gao F., et al. Isolation and structure of halistatin 1 from the eastern Indian Ocean marine sponge Phakellia carteri. J Org Chem 1993, 58(9):2538-2543.
5. Gravelos DG, Lake R, Blunt JW, Munro MHG, Litaudon MSP. Halichondrins: cytotoxic polyether macrolides. European Patent Office, Munich, Switzerland: Publication number EP 0 572 109 A1; 1993.
6. Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 1992, 55(1):31-51.
7. Bai R.L., Paull K.D., Herald C.L., Malspeis L., Pettit G.R., Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991, 266(24):15882-15889.
8. Towle M.J., Salvato K.A., Budrow J., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001, 61(3):1013-1021.
9. Luduena R.F., Roach M.C., Prasad V., Pettit G.R. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol 1993, 45(2):421-427.
10. Goel S., Mita A.C., Mita M., et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009, 15(12):4207-4212.
11. Fodstad O., Breistol K., Pettit G.R., Shoemaker R.H., Boyd M.R. Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts. J Exp Ther Oncol 1996, 1(2):119-125.
12. Aicher T.D., Buszek K.R., Fang F.G., et al. Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 1992, 114(8):3162-3164.
13. Yu M., Littlefield B., Kishi Y. Discovery of E7389, a Fully Synthetic Macrocyclic Ketone Analog of Halichondrin B. Anticancer agents from natural products 2005, CRC Press.
14. Mani S., Swami U. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer. Drugs Today (Barc) 2010, 46(9):641-653.
15. Jordan M.A., Kamath K., Manna T., et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005, 4(7):1086-1095.
16. Okouneva T., Azarenko O., Wilson L., Littlefield B.A., Jordan M.A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008, 7(7):2003-2011.
17. Dabydeen D.A., Burnett J.C., Bai R., et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 2006, 70(6):1866-1875.
18. Kuznetsov G., Towle M.J., Cheng H., et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004, 64(16):5760-5766.
19. F.D.A. U. S. Food and Drug Administration. Retreived on 16.11.10. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf.
20. U. S. National Institutes of Health Retreived on 13.11.10. http://clinicaltrials.gov/ct2/results%3Fterm=e7389.
21. National Cancer Institute Drug Dictionary - Definition of eribulin mesylate. Retreived on 13.11.10. http://www.cancer.gov/drugdictionary/%3FCdrID=257773.
22. Wang Y., Serradell N., Bolos J., Rosa E. Eribulin mesilate. Drugs Future 2007, 32(8):681-698.
23. Product information, USA, Eisai Inc.
24. National Cancer Institute, Division of Cancer Treatment and Diagnosis - Featured Agents. Retreived on 13.11.10. http://dctd.cancer.gov/FeaturedAgents/pdfs/E7389SolicitationMarch2005.pdf.
25. Kimura T., Synold T., Mahaffey C.M., et al. E7389, a novel antimicrotubule agent with potent p53-independent induction of p27, Bcl2 phosphorylation and cytotoxicity in nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003, 22. [abstr 2804].
26. Alley M.C., Smith A.C., Donohue S.J., Schweikart K.M., Newman D.J., Tomaszewski J.E. Comparison of the relative efficacies and toxicities of halichondrin B analogues. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther 2005, [abst C230].
27. Budman D.R., Calabro A., Littlefield BA Synergestic combinations of E7389 (halichondrin B analogue) with conventional agaents:In vitro median effect analysis in cell lines with potential clinical implications. 27th Annu San Antonio Breast Cancer Symp 2004, [abst 6055].
28. Kuznetsov G., TenDyke K., Towle M.J., et al. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol Cancer Ther 2009, 8(10):2852-2860.
29. Towle M.J., Agoulnik S., Kuznetsov G., et al. In vivo efficacy of E7389, a synthetic analogue of the marine sponge antitubulin agent halichondrin B, against human tumor xenografts under monotherapy and combination therapy conditions. Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd ed.). [abst 2749].
30. Wozniak K.M., Lapidus R.G., Wu Y., et al. Assessment of neuropathy-inducing effects of eribulin mesylate versus paclitaxel and ixabepilone in mice. Ann Oncol 2010, 21(Suppl. 8):viii42-viii62. [abstract 137P].
31. Bai R., Hamel E Interaction of [3H]halichondrin B with tubulin. Proc Am Assoc Cancer Res 2009, [abst 5570].
32. Okouneva T., Wilson L., Littlefield B.A., Jordan M.A. E7389 and ER-076349, synthetic halichondrin B analogs, suppress centromere dynamics in concert with mitotic block. Proc Am Assoc Cancer Res (AACR) 2001, 45. [abst 5436].
33. Kamath K., Okouneva T., Miller H., et al. E7389, a synthetic analog of halichondrin B, suppresses microtubule dynamics in living MCF7 cells by a novel mechanism. Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd ed.). [abst LB-43].
34. Smith J.A., Wilson L., Azarenko O., et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010, 49(6):1331-1337.
35. Smith J., Wilson L., Zhu X., Lewis B., Littlefield B., Jordan M.A. Eribulin (E7389) binds to 13 saturable sites at microtubule ends to inhibit microtubule dynamics. 99th AACR Annual Meeting 2008, [abst 1408].
36. Alday P.H., Correia J.J. Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation. Biochemistry 2009, 48(33):7927-7938.
37. Agoulnik S., Kuznetsov G., Tendyke K., et al. Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with ßIII tubulin isotype expression in human breast cancer cell lines. J Clin Oncol 2005, 23(16S):2012. Part I of II.
38. Stengel C., Newman S.P., Leese M.P., Potter B.V., Reed M.J., Purohit A. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 2010, 102(2):316-324.
39. Saussede-Aim J., Matera E.L., Herveau S., Rouault J.P., Ferlini C., Dumontet C. Vinorelbine induces beta3-tubulin gene expression through an AP-1 Site. Anticancer Res 2009, 29(8):3003-3009.
40. Seve P., Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol 2008, 9(2):168-175.
41. Synold T.W., Morgan R.J., Newman E.M., et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial. J Clin Oncol 2005, 23(16S):3036.
42. Synold T.W., Lawrence J., Xi B., Colevas A.D., Lewis M.D., Doroshow JH Human pharmacokinetics of E7389 (Halichondrin B analog), a novel anti-microtubule agent undergoing phase I investigation in the California Cancer Consortium (CCC). Proc Am Soc Clin Oncol 2003, 22. [abstr 575].
43. Tan A.R., Rubin E.H., Walton D.C., et al. Phase I study of eribulin mesylate administered once every 21days in patients with advanced solid tumors. Clin Cancer Res 2009, 15(12):4213-4219.
44. Minami H., Mukohara T., Nagai S., Mukai H., Namiki M. A phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer Suppl 2008, 6:140. [abst 446].
45. Witteveen P., Marchetti S., Mergui-Roelvink M., et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment. J Clin Oncol 2010, 28(15 Suppl.):2582.
46. Devriese L.A., Wanders J., Jenner A., et al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Abstract presented at the EORTC-NCI-AACR Symposium 2010, [abstract 574].
47. Swami U., Petrylak D.P., Raftopoulos H., et al. Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol 2010, 28(15 Suppl.). [abst 2589].
48. Jansen M., Vernaz-Gris M., DesJardins C., et al. Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC). J Clin Oncol 2009, 27(15S). [abst 2524].
49. Zheng W., Seletsky B.M., Palme M.H., et al. Structure-activity relationships of synthetic halichondrin B analog E7389: in vitro susceptibility to PgP-mediated drug efflux. Annual meeting of the American Association for Cancer Research, vol. 7 2003, [abst 2751].
50. Giannakakou P., Sackett D.L., Kang Y.K., et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997, 272(27):17118-17125.
51. Zhang Z.Y., King B.M., Pelletier R.D., Wong Y.N. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol 2008, 62(4):707-716.
52. Simon R., Rubinstein L., Arbuck S.G., Christian M.C., Freidlin B., Collins J. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997, 89(15):1138-1147.
53. Synold T.W., Tsao-Wei D.D., Quinn D.I., et al. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): a California Cancer Consortium Trial. J Clin Oncol 2010, 28(Suppl.):7s. [abst 2527].
54. Goel R., Chen E., Welch S., et al. Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J Clin Oncol 2009, 27(Suppl.). [abstr e13509].
55. Cortes J., Vahdat L., Blum J.L., et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010, 28(25):3922-3928.
56. Vahdat L.T., Pruitt B., Fabian C.J., et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009, 27(18):2954-2961.
57. Iwata H., Aogi K., Masuda N., et al. Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. J Clin Oncol 2010, 28(15 Suppl.):1081.
58. Gradishar W.J. The place for eribulin in the treatment of metastatic breast cancer. Curr Oncol Rep 2010, Nov 23 [Epub ahead of print].
59. Spira A.I., Iannotti N.O., Savin M.A., et al. Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007, 25(18S):7546.
60. Gitlitz B.J., Davies A.M., Belani C.P., et al. A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial. 2009 ASCO Annual Meeting. J Clin Oncol 2009, 27(Suppl.):15s. [abstr 8056].
61. de Bono J.S., Maroto P., Calvo E., et al. Phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapy. 2009 ASCO Genitourinary Cancers Symposium 2009, [abstract No. 166].
62. Scher H.I., Halabi S., Tannock I., et al. The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer. J Clin Oncol 2007, 25(18S):5057.
63. Stein M.N., Chen Y., Hudes G.R., Carducci M.A., Tan W., DiPaola RS ECOG 5805: a phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2010, 28(15 Suppl.):4556.
64. E7389 in Treating Patients With Recurrent Ovarian Epithelial PPC, or Fallopian Tube Cancer. http://clinicaltrials.gov/ct2/show/NCT00334893.
65. Hensley M.L., Kravetz S., Sima C., et al. Eribulin mesylate (halichondrin B Analog E7389) in platinum-resistant epithelial ovarian cancer (PR-EOC): a CTEP-sponsored phase II study. 2009 ASCO Annual Meeting. J Clin Oncol 2009, 27(Suppl.):15s. [abstr 5561].
66. Schoffski P., Ray-Coquard I.L., Cioffi A., et al. Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052). J Clin Oncol 2010, 28(15S):10031.
67. Moore M.J., Tang P., Renouf D., et al. A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer. J Clin Oncol 2009, 27(15S):e15634.
68. E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction. http://clinicaltrials.gov/ct2/show/NCT00365157.
69. Quinn D.I., Aparicio A., Tsao-Wei D.D., et al. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial. J Clin Oncol 2010, 28(15 Suppl.):4539.
70. Arnold S.M., Moon J., Williamson S.K., et al. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs 2009.
71. Twelves C., Cortes J., Vahdat L.T., Wanders J., Akerele C., Kaufman P.A. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010, 10(2):160-163.
72. Twelves C., Loesch D., Blum J.L., et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. ASCO Meeting Abstracts 2010, CRA1004.
73. Twelves C., Akerele C., Wanders J., Cortes J. Eribulin Mesylate (E7389) vs. Treatment of Physician's Choice (TPC) in Patients (Pts) with Metastatic Breast Cancer (MBC): Subgroup Analyses from the EMBRACE Study. Ann Oncol 2010, 21(Suppl. 8). viii96-viii121.
74. Narayan S., Carlson E., Cheng H., et al. Second generation eribulin analogs: efficacy against multi-drug resistant tumors and brain tumors. Proc Am Assoc Cancer Res 2009, [abstract nr 2704].
75. Hortobagyi G., Gomez H., Li R., et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010, 122(2):409-418.
76. Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007, 25(33):5210-5217.
77. Sparano J.A., Vrdoljak E., Rixe O., et al. Randomized Phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010, 28(20):3256-3263.
78. Martín M., Ruiz A., Muñoz M., et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007, 8(3):219-225.
79. Jones S., Winer E., Vogel C., et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995, 13(10):2567-2574.
80. Harvey V., Mouridsen H., Semiglazov V., et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006, 24(31):4963-4970.
81. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2 - negative metastatic breast cancer. J Clin Oncol 2010, 28(20):3239-3247.
82. Joensuu H., Sailas L., Alanko T., et al. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Ann Oncol 2010, 21(5):968-973.
83. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676.
84. Seidman A.D., Berry D., Cirrincione C., et al. Randomized Phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 Nonoverexpressors: final results of cancer and leukemia group B Protocol 9840. J Clin Oncol 2008, 26(10):1642-1649.
85. Bishop J.F., Dewar J., Toner G.C., et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999, 17(8):2355-2364.
86. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23(31):7794-7803.
87. National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology. Retrieved on 18.02.11. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.